Immunovant, Inc. Stock (NASDAQ: IMVT – get rating) have received an average rating of “Moderate Buy” from the seven brokerage houses that currently cover the company, MarketBeat reports. Two equity research analysts rated the stock with a hold recommendation and four issued a buy recommendation on the company. The average 12-month price target among analysts who have updated their coverage on the stock in the past year is $10.57.
Several analysts recently weighed in on IMVT’s stock. SVB Leerink raised its price target on Immunovant shares to $14.00 from $12.00 and gave the stock an “outperformer” rating in a research report on Friday. Chardan Capital lowered Immunovant’s share price target from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, September 29. Ultimately, UBS Group lowered Immunovant’s shares from a “buy” rating to a “neutral” rating and lowered its share price target from $7.00 to $5.00 in a research report on Monday, September 26.
Immunology Price Performance
Actions of NASDAQ: IMVT it rose $0.13 during midday trading on Friday, reaching $12.05. The company had a trading volume of 673,902 shares, compared to its average volume of 659,499. The company has a market cap of $1.4 billion, a P/E ratio of -8.20, and a beta of 1.21. Immunovant has a 12-month minimum of $3.14 and a 12-month maximum of $12.42. The company has a fifty day moving average of $7.37 and a two hundred day moving average of $5.43.
Immunovant (NASDAQ: IMVT – get rating) last published its quarterly earnings data on Friday, August 5. The company reported EPS ($0.35) for the quarter, beating the consensus estimate of ($0.40) by $0.05. Research analysts expect Immunovant to post -1.64 earnings per share for the current fiscal year.
Buying and selling insider information on Immunovant
In other Immunovant news, CEO Peter Salzmann sold 2,793 shares in a transaction that occurred on Thursday, October 13. The shares were sold at an average price of $9.18, for a total value of $25,639.74. Following the sale, the CEO now directly owns 997,953 shares of the company, valued at approximately $9,161,208.54. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, CEO Peter Salzmann sold 2,793 shares in a transaction on Thursday, October 13. The shares were sold at an average price of $9.18, for a total value of $25,639.74. Following the transaction, the CEO now directly owns 997,953 shares of the company, valued at approximately $9,161,208.54. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this link. Additionally, CFO Eva Renee Barnett sold 12,500 shares in a transaction on Tuesday, October 11. The shares were sold at an average price of $9.44, for a total transaction of $118,000.00. Following the completion of the transaction, the CFO now directly owns 272,857 shares of the company, valued at $2,575,770.08. Disclosure of this sale can be found here. In the last three months, the informants have sold 20,894 shares of the company valued at $178,229. Insiders own 3.00% of the company’s shares.
Institutional Marketing of Immunovant
Several hedge funds have recently made changes to their IMVT positions. Amalgamated Bank purchased a new share of Immunovant stock in the first quarter for $33,000. Barclays PLC purchased a new position in Immunovant stock in the third quarter valued at about $33,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Immunovant shares by 43.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,076 shares of the company valued at $44,000 after buying an additional 2,445 shares last quarter. Prospera Financial Services Inc bought a new position in Immunovant stock in the first quarter valued at around $50,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Immunovant stock in the second quarter valued at around $57,000. Institutional investors and hedge funds own 34.53% of the company’s shares.
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. Develops batoclimab, a novel fully human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, and has completed initiation of Phase II clinical trials. for the treatment of warm autoimmune hemolytic anemia.
This instant news alert was powered by MarketBeat’s financial data and narrative science technology to provide readers with the fastest and most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Immunovant, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five actions that major analysts quietly whisper to their clients to buy now before the broader market realizes it… and Immunovant was not on the list.
While Immunovant currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.